anonymous
Guest
anonymous
Guest
So word is that despite now having a dedicated hemostat sales force, the Ofirmev division will still have a realignment as they need to reduce the number of sales reps. What else could happen?
175 reps and ideal number 150 target territories.
How many hospital reps filled hemostat spots. Now the cutouts can be made since hemostats jobs are complete.
Low volume poor performing territories will be affected. Specifically the expansion territories if they are poor growth and volume performers.
It should be announced before EOY. Mallinckrodt ideally would not want to roll this into the new fiscal year.
Quit already. Find another job! What are you waiting for?!?! This is a dead end! No new products, crazy double digit growth,'more admin, call reporting around the corner, and a terrible reputation! Get out!!!!!